Lawsuit Alert: Investors Who Lost More Than $100,000 With Agenus Inc. (NASDAQ:AGEN) Shares Should Contact the Shareholders Foundation
SAN DIEGO, CA, September 18, 2024 (Newswire.com) - A lawsuit is pending for certain investors in Agenus Inc. (NASDAQ: AGEN) shares. Investors, who purchased shares in excess of $100,000 of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Agenus Inc. (NASDAQ:AGEN) shares.
Investors, who purchased shares in excess of $100,000 of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On July 18, 2024, Agenus Inc. announced the results of an "end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM)." The press release revealed that the "FDA advised against submission of these results in support of an Accelerated Approval based on their view that objective response rates may not translate to survival benefit."
On September 6, 2024, an investor in NASDAQ: AGEN shares filed a lawsuit over alleged securities laws violations by Agenus Inc. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than Defendants had led investors to believe, that accordingly, botensilimab and balstilimab's clinical results, as well as their regulatory and commercial prospects, were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Agenus Inc. (NASDAQ: AGEN) should contact the Shareholders Foundation, Inc.
CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
Contact Information
Michael Daniels
Manager
mail@shareholdersfoundation.com
858-779-1554
SOURCE: Shareholders Foundation, Inc.
Source: Shareholders Foundation, Inc.
Related Media
